Please use this identifier to cite or link to this item:
Title: PTE Provisions Relating to Pharmaceutical Products in Australia in Comparison with European SPC and USA PTE
Authors: Joshi, Omkar
Roy, Archna
Janodia, Manthan
Keywords: TGA;ARTG;Section 223;Escitalopram;Lohman
Issue Date: May-2015
Publisher: NISCAIR-CSIR, India
Abstract: Pharmaceutical products in Australia can win up to five years of Patent Term Extension (PTE). This article reviews Australian PTE Law and its relationship with regulatory pathway for approving medicinal products. The article describes recent PTE cases involving pharmaceutical products and analyses how effective these PTE provisions are in Australia. Finally, it compares PTE provisions in Australia with European SPC (Supplementary Protection Certificate) and USA PTE Provisions.
Page(s): 147-154
ISSN: 0975-1076 (Online); 0971-7544 (Print)
Appears in Collections:JIPR Vol.20(3) [May 2015]

Files in This Item:
File Description SizeFormat 
JIPR 20(3) 147-154.pdf100.85 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.